Abstract:Abstract Mild micro-hepatic encephalopathy (MHE) is a severe complication of cirrhosis. At present, there are differences in the consistency of detection strategies and treatment directions for MHE. The characteristic changes in intestinal microbiota and serum metabolites in MHE patients and the possible relevant interaction mechanisms would inevitably affect the developmental direction of MHE. Therefore, the changes in the characteristics of intestinal microbiota and serum metabolites of MHE patients were determined, and the possible interactions between them were analyzed. Stool and serum tests were performed on both the MHE patients and healthy individuals. The 16S rRNA gene high-throughput sequencing and bioinformatics analyses were used to analyze the differences in intestinal microbiota in MHE patients. The serum metabolites were detected using liquid LC-MS/MS (liquid chromatography-mass spectrometry) technology, and the differences in the metabolic networks of blood metabolites in MHE patients were analyzed. A comprehensive bioinformatics analysis approach was adopted to identify the composition and characteristics of microbiota and serum metabolites and the possible correlation between them. The main characteristics of the structural imbalance in the intestinal microbiota of MHE patients included a decrease in the number of beneficial bacteria at the levels of phylum, class, order, family, and genus and an increase in the pathogenic bacteria, resulting in substantial changes in the relative abundances of bacteria in the intestinal microbiota. The main predicted functions that showed significant differences included chromosome, amino acid-related enzymes, methane metabolism, and arginine and proline metabolism. The detection of serum metabolites resulted in 10 different metabolites, including taurocholic acid, citrulline, d -phenyl-lactic acid, l -tyrosine, benzoate, phenylalanine, linoleic acid, eicosapedienic acid, alpha-dimorphecolic acid, and dehydroepiandrosterone. The subsequent metabolite pathways analysis showed differences in the metabolism of linoleic acid, phenyl-propane, caffeine, arginine, proline, glycine, serine, threonine, tyrosine, and pyrimidine compared to the control group. In summary, it seems that the changes in the microbiome that we have identified have resulted in corresponding changes to the serum metabolome. In turn, this may represent changes in the absorption of metabolites from the gut or reflect the changed metabolic capacity of the MHE liver or both. There were characteristic changes in the intestinal microbiota and serum metabolites in the MHE patients. There might be a related interaction mechanism between the two, which would provide evidence and direction for the detection and treatment strategies of MHE.

Microbiota-gut-liver-brain axis and hepatic encephalopathy

The Role of Intestinal Bacteria and Gut–Brain Axis in Hepatic Encephalopathy

Navigating the Gut-brain Axis: Insights into the Pathogenesis of Hepatic Encephalopathy

Gut Dysbiosis and Blood-Brain Barrier Alteration in Hepatic Encephalopathy: From Gut to Brain

Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis

Novel Insights into Pathogenesis and Therapeutic Strategies of Hepatic Encephalopathy, from the Gut Microbiota Perspective

Fecal Microbiota Transplantation for Treating Hepatic Encephalopathy: Experimental and Clinical Evidence and Possible Underlying Mechanisms

Hepatic encephalopathy: From novel pathogenesis mechanism to emerging treatments

Hepatic encephalopathy: current challenges and future prospects

Advances in the diagnosis and treatment of hepatic encephalopathy

The neurogliovascular unit in hepatic encephalopathy

A Meta-Analysis of Microbiome Therapies for Hepatic Encephalopathy

Infection, inflammation and hepatic encephalopathy from a clinical perspective

Pathophysiology of hepatic encephalopathy: The concept of synergism

Expert Insights: The Potential Role Of The Gut Microbiome-Bile Acid-Brain Axis In The Development And Progression Of Alzheimer'S Disease And Hepatic Encephalopathy

Characterization of intestinal microbiota and serum metabolites in patients with mild hepatic encephalopathy

Hericium Erinaceus Polysaccharides Ameliorate Nonalcoholic Fatty Liver Disease Via Gut Microbiota and Tryptophan Metabolism Regulation in an Aged Laying Hen Model

Hepatic encephalopathy – recent advances in treatment and diagnosis

Faecal hsa-miR-7704 inhibits the growth and adhesion of Bifidobacterium longum by suppressing ProB and aggravates hepatic encephalopathy

Research Progress on Hepatic Encephalopathy: Animal Models and Disease Mechanisms

Effect of Probiotic Treatment on Cirrhotic Patients with Minimal Hepatic Encephalopathy: A Meta-Analysis.